

3rd December, 2015

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001
Dear Sir,

National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400 051

Scrip Code: BSE - AJANTPHARM 532331/ NSE - AJANTPHARM EQ

Sub.: Launch of Montelukast IR Tablets and Montelukast Chewable Tablets in US market

Dear Sir/Madam,

We are pleased to inform that our Company's subsidiary viz., Ajanta Pharma USA Inc. has launched Montelukast IR Tablets and Montelukast Chewable Tablets in US market. We enclose herewith a press release being issued by the company in this regard, for your information and records.

Please acknowledge the receipt.

Thanking You,

Yours faithfully,

For AJANTA PHARMA LIMITED



GAURANG SHAH
Sr. G.M. - Legal &
Company Secretary

Encl.: a/a

BSE: 532331**NSE:** AJANTPHARM**Reuters:** AJPH.NS**Bloomberg:** AJP:IN

Ajanta Pharma Announces the Launch of Montelukast IR Tablets and Montelukast Chewable Tablets

Mumbai, India - (December 03rd, 2015) - Ajanta Pharma USA Inc., a subsidiary of Ajanta Pharma Limited, announced today the launch of Montelukast Sodium IR Tablets (10mg) and Montelukast Sodium Chewable Tablets (4mg & 5mg), generic versions of SINGULAIR® Tablets and SINGULAIR® Chewable Tablets, respectively. The United States Food & Drug Administration (US FDA) approval extends the breadth of the Montelukast offerings from Ajanta Pharma into three dosage forms (Immediate-Release Tablets, Chewable Tablets, and Oral Granules).

Montelukast IR Tablets and Chewable Tablets are part of an ever-growing portfolio that Ajanta Pharma has developed for the US market. To date, the US FDA has granted Ajanta Pharma five ANDA final approvals and two ANDA tentative approvals. An additional 19 ANDAs are pending approval from the US FDA.

About Ajanta Pharma

Ajanta Pharma Limited is a fully-integrated pharmaceutical company with global headquarters in Mumbai, India. Over 6,000 employees are engaged in developing, manufacturing and marketing of quality finished dosages across 35 countries. Its mission is to serve global healthcare needs through empathy, innovation and technology.

For more details about Ajanta Pharma USA Inc., please visit us at www.ajantapharmausa.com.

For Ajanta Pharma Ltd., you may visit us at www.ajantapharma.com.

For specific queries, contact:

Rajeev Agarwal Tel: +91 22 66061377 Email: rajeev.agarwal@ajantapharma.com

SINGULAIR® is a registered trademark of Merck & Co., Inc.

[Safe Harbour Statement](#)



CIN: L24230MH1979PLC022059

Registered Office: 98, Ajanta House, Charkop, Kandivili (West), Mumbai, 400 067, India.